Christoph Zielinski

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Zielinski et al. · The Lancet · 2009 · 1.1K citations · Full text

Non-small-cell Lung Cancer, Medicine, Cancer Management +6

Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer

Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg et al. · Journal of Clinical Oncology · 2017 · 848 citations · Full text

Trametinib Treatment, Conclusion Dabrafenib, Medicine +15

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

Nathan I. Cherny, Richard Sullivan, Urania Dafni et al. · Annals of Oncology · 2015 · 792 citations · Full text

Oncology, Clinical Benefit Scale, Anti-cancer Therapies +8

Prediction of venous thromboembolism in cancer patients

Cihan Ay, Daniela Dunkler, Christine Marosi et al. · Blood · 2010 · 759 citations · Full text

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

Gϋnter von Minckwitz, Andreas du Bois, Marcus Schmidt et al. · Journal of Clinical Oncology · 2009 · 687 citations